NCT05496166View on ClinicalTrials.gov

The Efficiency of Surgery and Radiotherapy After SHR-1316 (Adebrelimab) and Platinum-containing Doublet Induction Therapy for Limited-stage Small Cell Lung Cancer

PHASE3Not yet recruitingINTERVENTIONAL

Enrollment

348

Participants

Timeline

Start Date

August 1, 2023

Primary Completion Date

August 1, 2027

Study Completion Date

August 1, 2030

Conditions

Limited Stage Small Cell Lung Cancer

Interventions

COMBINATION_PRODUCT

chemotherapy and SHR-1316(Adebrelimab) comnined with surgery or radiotherapy

Induction treatment stage: SHR-1316(Adebrelimab)，20mg/kg,+Cisplatin 75mg/m2, d1+ etoposide 100mg/m2, d1,d2,d3, q3w, iv, 4 cycles. Patients who are able to receive surgery after assessed by two surgons would receive surgery or radiotherapy randomly. Adjuvant/ maintenance treatment stage: SHR-1316，20mg/kg, iv, q3w,up to 1 year

Trial Locations (1)

200433

Shanghai Pulmonary Hospital, Shang'ai

All Listed Sponsors

collaborator

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY

lead

Shanghai Pulmonary Hospital, Shanghai, China

OTHER

NCT05496166 - The Efficiency of Surgery and Radiotherapy After SHR-1316 (Adebrelimab) and Platinum-containing Doublet Induction Therapy for Limited-stage Small Cell Lung Cancer | Biotech Hunter | Biotech Hunter